Security News
FDA Approves Teva’s Denosumab Biosimilar Ponlimsi™ (denosumab-adet)
UnknownApr 15, 2026(27 days ago)
FDA Approves Teva’s Denosumab Biosimilar Ponlimsi™ (denosumab-adet)
On March 30, 2026, the FDA approved Teva’s biosimilar Ponlimsi™ (denosumab-adet), referencing Amgen’s Prolia® (denosumab), for all indications of the reference product.... By: Venable LLP
Related News
[Video] Daily Compliance News: May 12, 2026, The TACO Don Goes to China Edition
Unknown27 minutes ago
Shai Hulud attack ships signed malicious TanStack, Mistral npm packages
Unknownabout 1 hour ago
Claude Mythos Finds Only One Curl Vulnerability; Experts Divided on What It Really Means
Unknownabout 1 hour ago